Zobrazeno 1 - 10
of 105
pro vyhledávání: '"Gendicine"'
Publikováno v:
Genes and Diseases, Vol 11, Iss 4, Pp 101155- (2024)
Genetic mutations in TP53 contribute to human malignancies through various means. To date, there have been a variety of therapeutic strategies targeting p53, including gene therapy to restore normal p53 function, mutant p53 rescue, inhibiting the MDM
Externí odkaz:
https://doaj.org/article/325012175f654985989117d235f7778f
Autor:
Jagadish Hosmani, Shazia Mushtaq, Shahabe Saquib Abullais, Hussain Mohammed Almubarak, Khalil Assiri, Luca Testarelli, Alessandro Mazzoni, Shankargouda Patil
Publikováno v:
Medicina, Vol 57, Iss 5, p 438 (2021)
Background and Objectives: Oral cancer is the 6th most common cancer in the world and oral leukoplakia is an oral potentially malignant disorder that could develop into oral cancer. This systematic review focusses on randomized clinical trials for re
Externí odkaz:
https://doaj.org/article/9329dd38eb104e4db57ee9fb4bd29188
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Wei Guo, Jianguo Zhang, Yi Li, Guilin Huang, Moyi Sun, Longjiang Li, Kai Yang, Wei Ran, Xiuqin Li, Zhangui Tang
Publikováno v:
International Journal of Oral Science, Vol 13, Iss 1, Pp 1-6 (2021)
International Journal of Oral Science
International Journal of Oral Science
The first gene therapy product, recombinant adenovirus human p53 (rAd-p53), has been approved by CFDA since 2013. During these years, most of the clinical trials and the relevant basic research were carried out by Chinese oncologists. Gendicine was p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2af19222ab4c57ca741d4b9e2e811c5a
https://doaj.org/article/d58a102c0f7349e89574158df0039104
https://doaj.org/article/d58a102c0f7349e89574158df0039104
Publikováno v:
Current Gene Therapy. 20:127-141
Suppression of TP53 function is nearly ubiquitous in human cancers, and a significant fraction of cancers have mutations in the TP53 gene itself. Therefore, the wild-type TP53 gene has become an important target gene for transformation research of ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12bc41458ce7248b8f11b08653cb83b0
https://doi.org/10.2174/1566523220999200731003206
https://doi.org/10.2174/1566523220999200731003206
Publikováno v:
Human Gene Therapy. 31:881-890
The aim is to investigate the genomic characterization of uterine sarcoma for rAd-p53 (Gendicine®) combined with chemotherapy treatment. We recently published an article on 12 cases of uterine sarcomas, which were treated with rAd-p53 combined with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2624590a6eda0054991664b72f24056c
https://doi.org/10.1089/hum.2019.305
https://doi.org/10.1089/hum.2019.305
Autor:
Alessandro Mazzoni, Shahabe Saquib Abullais, Khalil Ibrahim Assiri, Luca Testarelli, Shankargouda Patil, Jagadish Hosmani, Shazia Mushtaq, Hussain Almubarak
Publikováno v:
Medicina, Vol 57, Iss 438, p 438 (2021)
Background and Objectives: Oral cancer is the 6th most common cancer in the world and oral leukoplakia is an oral potentially malignant disorder that could develop into oral cancer. This systematic review focusses on randomized clinical trials for re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c4389bc1be9f902b8f487a0bab65180
https://www.mdpi.com/1648-9144/57/5/438
https://www.mdpi.com/1648-9144/57/5/438
Autor:
Jagadish, Hosmani, Shazia, Mushtaq, Shahabe Saquib, Abullais, Hussain Mohammed, Almubarak, Khalil, Assiri, Luca, Testarelli, Alessandro, Mazzoni, Shankargouda, Patil
Publikováno v:
Medicina
Background and Objectives: Oral cancer is the 6th most common cancer in the world and oral leukoplakia is an oral potentially malignant disorder that could develop into oral cancer. This systematic review focusses on randomized clinical trials for re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8f7a264f5cf3fa97592b373903161858
https://pubmed.ncbi.nlm.nih.gov/34062896
https://pubmed.ncbi.nlm.nih.gov/34062896
Autor:
María Tristán-Manzano, Pedro Justicia-Lirio, Noelia Maldonado-Pérez, Marina Cortijo-Gutiérrez, Karim Benabdellah, Francisco Martin
Publikováno v:
Digibug: Repositorio Institucional de la Universidad de Granada
Universidad de Granada (UGR)
Digibug. Repositorio Institucional de la Universidad de Granada
Consejo Superior de Investigaciones Científicas (CSIC)
Frontiers in Immunology, Vol 11 (2020)
Universidad de Granada (UGR)
Digibug. Repositorio Institucional de la Universidad de Granada
Consejo Superior de Investigaciones Científicas (CSIC)
Frontiers in Immunology, Vol 11 (2020)
We thank GENYO Institute and LentiStem Biotech for the support to compile of the necessary information to write this review. We also thank Fundación Poco Frecuente (FPF) and Asociación Española de Enfermos con Glucogenosis (AEEG) for their kindly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e7e6e1c8f1fe4cf337182dbda8af29f
http://hdl.handle.net/10481/64049
http://hdl.handle.net/10481/64049
Publikováno v:
Human Gene Therapy. 29:242-250
This study evaluated the efficacy of rAd-p53 (Gendicine®) followed by chemotherapy for the treatment of uterine sarcoma. Twelve cases of uterine sarcoma treated at Shengjing Hospital were retrospectively analyzed. Among the 12 patients, one had prim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c2e8cd93d3e730f15d46e2ade745f41
https://doi.org/10.1089/hum.2017.206
https://doi.org/10.1089/hum.2017.206